title: Para-aortic lymph node metastasis in relation to serum CA 125 levels and nuclear grade in endometrial carcinoma.
abstract: BACKGROUND
  To investigate the relationship between preoperative serum CA 125 levels and para-aortic lymph node (PAN) metastasis as determined by systematic pelvic and para-aortic lymph node dissection in endometrial carcinoma.
  
  
  METHODS
  This study included 180 patients (n = 55, premenopausal; n = 125, postmenopausal) with endometrial carcinoma treated by complete surgical staging. Cut-off values of preoperative serum CA 125 levels for PAN metastasis were determined by receiver characteristic curve (ROC) analysis. Logistic regression analysis was used to determine independent predictors for PAN metastasis.
  
  
  RESULTS
  The median serum CA 125 levels of patients with PAN metastasis were significantly higher than the levels of those with no metastasis in both premenopausal and postmenopausal groups. Based on ROC analysis, we could determine four cut-off values (70 and 210 U/mL for premenopausal patients, 20 and 60 U/mL for postmenopausal patients) and categorize the serum CA 125 levels into low, moderate and high groups. By logistic regression analysis, the CA 125 level and nuclear grade were found to be significant predictors of PAN metastasis, respectively. Using this model, the patients were stratified into three risk groups. The probabilities of PAN metastasis for patients in the low-risk, intermediate-risk and high-risk groups were less than 2%, 2-25% and more than 50%, respectively.
  
  
  CONCLUSIONS
  Serum CA 125 levels and nuclear grade are important risk factors for PAN metastasis in endometrial carcinoma.
authors.affiliation: Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Sapporo, Japan.
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Ebina
authors.forename: Noriaki
authors.initials: N
authors.lastname: Sakuragi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Hareyama
authors.forename: Yukiharu
authors.initials: Y
authors.lastname: Todo
authors.forename: Eij
authors.initials: E
authors.lastname: Nomura
authors.forename: Mahito
authors.initials: M
authors.lastname: Takeda
authors.forename: Kazuhira
authors.initials: K
authors.lastname: Okamoto
authors.forename: Hideto
authors.initials: H
authors.lastname: Yamada
authors.forename: Ritsu
authors.initials: R
authors.lastname: Yamamoto
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Fujimoto
mesh_terms: D000328:Adult; D000368:Aged; D001013:Aorta, Thoracic; D014408:Biomarkers, Tumor / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood*; D002277:Carcinoma / Q000097:blood* / Q000276:immunology / Q000556:secondary*; D016889:Endometrial Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000175:diagnosis; D008875:Middle Aged; D010388:Pelvis; D011237:Predictive Value of Tests; D011300:Preoperative Care; D012372:ROC Curve
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen